Amphastar Pharmaceuticals Hits Day Low of $19.83 Amid Price Pressure

Amphastar Pharmaceuticals, Inc. experienced significant volatility today, with the stock hitting an intraday low of USD 19.83. The company, operating within the Pharmaceuticals & Biotechnology sector, has seen a notable decline of -23.63% in its stock price as of February 27, 2026. This performance starkly contrasts with the S&P 500, which recorded a modest decline of -0.43% on the same day. Over the past week, Amphastar's stock has dropped -29.09%, while its one-month performance reflects a decrease of -22.93%. The year-to-date performance stands at -24.46%, indicating a challenging period for the small-cap company. In the last year, Amphastar has underperformed significantly, with a decline of -35.76%, compared to the S&P 500's gain of 17.36%. Financial metrics reveal a P/E ratio of 9.00 and a return on equity of 14.12%, suggesting a mixed financial outlook. The company's market capitalization is approximately USD 1,541 million, and it maintains a debt-to-equity ratio of 0.44. As Amphastar navigates these market conditions, its performance continues to draw attention within the industry.